These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6624652)

  • 21. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.
    Kim SY; Benowitz NL
    Drug Saf; 1990; 5(6):393-420. PubMed ID: 2285495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiarrhythmic effect related to the plasma concentration of pentisomide in vivo and the antiarrhythmic-concentration relationship in vitro.
    Hachisu M; Chen H; Soneda T; Fujishima K; Ishizuka T; Konno F
    Drugs Exp Clin Res; 1995; 21(4):145-51. PubMed ID: 8529527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs.
    Woosley RL; Roden DM
    Am J Cardiol; 1987 Apr; 59(11):19E-25E. PubMed ID: 3554949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The importance of pharmacokinetics and pharmacodynamics in the clinical evaluation of antiarrhythmic drugs.
    Kates RE
    G Ital Cardiol; 1986 Aug; 16(8):675-7. PubMed ID: 3792734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of evoked endocardial response for assessment of antiarrhythmic drug effects on myocardium.
    Furukawa T; Taniguchi K; Takeuchi J
    Bull Tokyo Med Dent Univ; 1988 Sep; 35(3):33-44. PubMed ID: 2466578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents.
    Follath F
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S41-3. PubMed ID: 1279308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic therapy of ventricular arrhythmias.
    Winkle RA; Glantz SA; Harrison DC
    Am J Cardiol; 1975 Oct; 36(5):629-50. PubMed ID: 1103605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacology of antiarrhythmic drugs: variability of metabolism and dose requirements.
    Follath F
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S74-6. PubMed ID: 1723123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical consequences of the lipophilicity and plasma protein binding of antiarrhythmic drugs and active metabolites in man.
    Drayer DE
    Ann N Y Acad Sci; 1984; 432():45-56. PubMed ID: 6151820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methods for documenting antiarrhythmic efficacy.
    Harrison DC
    Am J Cardiol; 1983 Sep; 52(6):37C-40C. PubMed ID: 6194680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Considerations for prophylactic use of antiarrhythmic drugs in acute myocardial infarction.
    Halkin H
    Cardiovasc Clin; 1974; 6(2):119-29. PubMed ID: 4613455
    [No Abstract]   [Full Text] [Related]  

  • 32. Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring.
    Takada M; Goto T; Kotake T; Saito M; Kawato N; Nakai M; Gunji T; Shibakawa M
    J Clin Pharm Ther; 2005 Feb; 30(1):5-12. PubMed ID: 15658999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cibenzoline plasma concentration and antiarrhythmic effect.
    Brazzell RK; Aogaichi K; Heger JJ; Somberg JC; Carliner NH; Morganroth J
    Clin Pharmacol Ther; 1984 Mar; 35(3):307-16. PubMed ID: 6697638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic drug monitoring: antiarrhythmic drugs.
    Campbell TJ; Williams KM
    Br J Clin Pharmacol; 2001; 52 Suppl 1(Suppl 1):21S-34S. PubMed ID: 11564050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.
    Mason JW
    N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of antiarrhythmic drugs.
    Woosley RL; Shand DG
    Am J Cardiol; 1978 May; 41(6):986-95. PubMed ID: 352124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein binding in antiretroviral therapies.
    Boffito M; Back DJ; Blaschke TF; Rowland M; Bertz RJ; Gerber JG; Miller V
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):825-35. PubMed ID: 14585213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of antiarrhythmic drugs on choline uptake in cardiac cells in culture.
    Rabkin SW
    Cardiovasc Res; 1992 Jan; 26(1):67-71. PubMed ID: 1516114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of N-acetylprocainamide.
    Connolly SJ; Kates RE
    Clin Pharmacokinet; 1982; 7(3):206-20. PubMed ID: 6178545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.